Officer Harlan Robins Files Intent to Sell $6.8M in Shares Following Recent Vesting
Summary
An officer of Adaptive Biotechnologies Corp, Harlan S. Robins, has filed a Form 144 indicating an intent to sell 470,266 shares of common stock, valued at approximately $6.83 million.
Key Events
-
Officer Files Intent to Sell
Harlan S. Robins, an officer of Adaptive Biotechnologies Corp, has filed a Form 144 to sell 470,266 shares of common stock.
-
Substantial Value
The proposed sale has an approximate market value of $6,828,262.32, representing a significant transaction.
-
Shares from Vesting Awards
The securities to be sold were acquired upon the vesting of restricted stock units and performance stock units on March 4, 2026.
-
Follows Recent Sales
This intent to sell follows previous sales by Mr. Robins in early March 2026, totaling 77,021 shares for gross proceeds of $1,355,892.14 over the past three months.
Analysis
This Form 144 indicates a significant intent to sell shares by Harlan S. Robins, an officer of Adaptive Biotechnologies Corp. The proposed sale of approximately $6.83 million in common stock represents a notable transaction for a company of this size. While the shares were acquired through the vesting of restricted and performance stock units, the substantial value and the filer's executive role make this a material event. This filing also follows a pattern of recent sales by Mr. Robins, suggesting ongoing liquidity or portfolio rebalancing. Investors should monitor the actual execution of these sales and consider the potential impact of this insider activity on market sentiment.
At the time of this filing, ADPT was trading at $13.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $6.68 to $20.76. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.